Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05220722
Title Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors TriSalus Life Sciences, Inc.

hepatocellular carcinoma

intrahepatic cholangiocarcinoma


Pembrolizumab + SD-101

Ipilimumab + Nivolumab + SD-101

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.